AKTivate Therapeutics' Acquisition

AKTivate Therapeutics was acquired by Virax on October 17, 2014.

AKTivate Therapeutics is conducting clinical trials in breast and ovarian cancers that are resistant to chemotherapy. The trials use a molecule called triciribine phosphate monohydrate to block AKT, t…

Articles about AKTivate Therapeutics' Acquisition: